CU23002A1 - Método de obtención de agregados antigénicos y su uso en formulaciones - Google Patents
Método de obtención de agregados antigénicos y su uso en formulacionesInfo
- Publication number
- CU23002A1 CU23002A1 CU20000279A CU20000279A CU23002A1 CU 23002 A1 CU23002 A1 CU 23002A1 CU 20000279 A CU20000279 A CU 20000279A CU 20000279 A CU20000279 A CU 20000279A CU 23002 A1 CU23002 A1 CU 23002A1
- Authority
- CU
- Cuba
- Prior art keywords
- structures
- resulting
- formulations
- aggregation
- antigenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con el método para la obtención de estructuras antigénicas de naturaleza agregada, capaces de potenciar la respuesta inmune a antígenos agregados administrados por vía sistémica y/o mucosal, generando potentes respuestas inmunes así coma estructuras químicas resultantes de la aplicación de este método, formulaciones obtenidas a partir de dichas estructuras y uso de las mismas. El método describe la obtención de nuevas estructuras antigénicas agregadas a partir del uso de agentes o compuestos agregantes, delipidantes u oxidantes que permiten la liberación de lípidos de la partícula y la agregación de las mismas de forma heterogénea, seleccionándose posteriormente agregados de partículas de tallas entre 30 y 500 nm mediante un proceso de exclusión molecular. También se puede provocar el estado de agregación en el interior de la levadura variando las condiciones de incubación. Las estructuras resultantes pueden utilizarse convenientemente adyuvadas o en una formulación donde pueden introducirse varios antígenos, encontrándose un efecto sinérgico entre estos componentes con respecto a la inmunogenicidad de la respuesta obtenida. Además la preparación puede contener, estabilizadores y preservos. Las estructuras antigénicas resultantes son aplicables en la industria farmacéutica como formulaciones vacunales preventivas o terapéuticas tanto para el uso humano como veterinario y como parte de sistemas de diagnóstico.
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20000279A CU23002A1 (es) | 2000-12-01 | 2000-12-01 | Método de obtención de agregados antigénicos y su uso en formulaciones |
RU2003119455/13A RU2266754C2 (ru) | 2000-12-01 | 2001-11-29 | Способ получения антигенных агрегатов и их применение в препаратах |
AT01998363T ATE465752T1 (de) | 2000-12-01 | 2001-11-29 | Verfahren zur gewinnung delipidierter antigener aggregate von hepatitis b und deren verwendung |
DE60141978T DE60141978D1 (de) | 2000-12-01 | 2001-11-29 | Verfahren zur gewinnung delipidierter antigener aggregate von hepatitis b und deren verwendung |
AU2002221518A AU2002221518B2 (en) | 2000-12-01 | 2001-11-29 | Method for obtaining antigenic aggregates and the use thereof in formulations |
CA2429543A CA2429543C (en) | 2000-12-01 | 2001-11-29 | Method for obtaining antigenic aggregates and the use thereof in formulations |
PCT/CU2001/000009 WO2002043756A2 (es) | 2000-12-01 | 2001-11-29 | Método de obtención de agregados antigénicos y su uso en formulaciones |
BR0115859-7 BRPI0115859B8 (pt) | 2000-12-01 | 2001-11-29 | método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina |
AU2151802A AU2151802A (en) | 2000-12-01 | 2001-11-29 | Method for obtaining antigenic aggregates and the use thereof in formulations |
ARP010105554A AR031437A1 (es) | 2000-12-01 | 2001-11-29 | Metodo de obtencion de agregados antigenicos y su uso en formulaciones |
PT01998363T PT1346727E (pt) | 2000-12-01 | 2001-11-29 | Método para a obtenção de agregados antigénicos e a sua utilização em formulações |
JP2002545726A JP4974441B2 (ja) | 2000-12-01 | 2001-11-29 | 抗原性凝集物を得る方法と製剤におけるその使用 |
EP01998363A EP1346727B1 (en) | 2000-12-01 | 2001-11-29 | Method for obtaining delipidated hepatitis b antigenic aggregates and their use thereof |
US10/433,492 US20040202676A1 (en) | 2000-12-01 | 2001-11-29 | Method for obtaining antigenic aggregates and the use thereof in formulations |
ES01998363T ES2342150T3 (es) | 2000-12-01 | 2001-11-29 | Procedimiento de obtencion de agregados antigenicos de la hepatitis b deslipidados y uso de los mismos. |
CNB018198236A CN1253206C (zh) | 2000-12-01 | 2001-11-29 | 获得抗原性聚集物的方法及其在制剂中的用途 |
KR1020037007094A KR100873675B1 (ko) | 2000-12-01 | 2001-11-29 | 항원응집체의 수득방법 및 제제에서의 이의 용도 |
ZA200303948A ZA200303948B (en) | 2000-12-01 | 2003-05-21 | Method for obtaining antigenic aggregates and the use thereof in formulations. |
US11/870,088 US20090104223A1 (en) | 2000-12-01 | 2007-10-10 | Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20000279A CU23002A1 (es) | 2000-12-01 | 2000-12-01 | Método de obtención de agregados antigénicos y su uso en formulaciones |
Publications (1)
Publication Number | Publication Date |
---|---|
CU23002A1 true CU23002A1 (es) | 2004-11-18 |
Family
ID=5459569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20000279A CU23002A1 (es) | 2000-12-01 | 2000-12-01 | Método de obtención de agregados antigénicos y su uso en formulaciones |
Country Status (17)
Country | Link |
---|---|
US (2) | US20040202676A1 (es) |
EP (1) | EP1346727B1 (es) |
JP (1) | JP4974441B2 (es) |
KR (1) | KR100873675B1 (es) |
CN (1) | CN1253206C (es) |
AR (1) | AR031437A1 (es) |
AT (1) | ATE465752T1 (es) |
AU (2) | AU2151802A (es) |
BR (1) | BRPI0115859B8 (es) |
CA (1) | CA2429543C (es) |
CU (1) | CU23002A1 (es) |
DE (1) | DE60141978D1 (es) |
ES (1) | ES2342150T3 (es) |
PT (1) | PT1346727E (es) |
RU (1) | RU2266754C2 (es) |
WO (1) | WO2002043756A2 (es) |
ZA (1) | ZA200303948B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23405A1 (es) * | 2003-10-20 | 2009-08-04 | Ct Ingenieria Genetica Biotech | Composiciones farmacéuticas para uso terapéutico |
EP1652914A1 (en) * | 2004-10-27 | 2006-05-03 | Berna Biotech AG | Virosome particles comprising antigens from influenza virus and Hepatitis B virus |
US9603921B2 (en) * | 2004-10-27 | 2017-03-28 | Janssen Vaccines Ag | Virosome particles comprising antigens from influenza virus and hepatitis b virus |
ES2401706T3 (es) | 2005-07-27 | 2013-04-23 | Eli Lilly And Company | Un método de tratar células cancerosas para crear una célula cancerosa modificada que provoca una respuesta inmunogénica |
CU23740A1 (es) * | 2009-09-29 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
AR107262A1 (es) | 2016-01-27 | 2018-04-11 | Lilly Co Eli | Inactivación de patógenos por delipidación |
CN109219449B (zh) * | 2016-03-31 | 2022-08-30 | 遗传工程与生物技术中心 | 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8421282D0 (en) | 1984-08-22 | 1984-09-26 | Connaught Lab | Multispecific antigenic proteins |
ES2039229T3 (es) * | 1986-01-14 | 1993-09-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos. |
US5728804A (en) * | 1995-06-02 | 1998-03-17 | Research Corporation Technologies, Inc. | Use of cyclodextrins for protein renaturation |
ES2260235T3 (es) * | 2000-06-22 | 2006-11-01 | Ucb Pharma Limited | Modificacion del antigeno "core" de la hepatitis b. |
US8092734B2 (en) * | 2004-05-13 | 2012-01-10 | Aptina Imaging Corporation | Covers for microelectronic imagers and methods for wafer-level packaging of microelectronics imagers |
-
2000
- 2000-12-01 CU CU20000279A patent/CU23002A1/es unknown
-
2001
- 2001-11-29 AU AU2151802A patent/AU2151802A/xx active Pending
- 2001-11-29 DE DE60141978T patent/DE60141978D1/de not_active Expired - Lifetime
- 2001-11-29 BR BR0115859-7 patent/BRPI0115859B8/pt not_active IP Right Cessation
- 2001-11-29 JP JP2002545726A patent/JP4974441B2/ja not_active Expired - Lifetime
- 2001-11-29 ES ES01998363T patent/ES2342150T3/es not_active Expired - Lifetime
- 2001-11-29 WO PCT/CU2001/000009 patent/WO2002043756A2/es active Application Filing
- 2001-11-29 RU RU2003119455/13A patent/RU2266754C2/ru active
- 2001-11-29 CA CA2429543A patent/CA2429543C/en not_active Expired - Fee Related
- 2001-11-29 AR ARP010105554A patent/AR031437A1/es not_active Application Discontinuation
- 2001-11-29 CN CNB018198236A patent/CN1253206C/zh not_active Expired - Lifetime
- 2001-11-29 KR KR1020037007094A patent/KR100873675B1/ko active IP Right Grant
- 2001-11-29 PT PT01998363T patent/PT1346727E/pt unknown
- 2001-11-29 EP EP01998363A patent/EP1346727B1/en not_active Expired - Lifetime
- 2001-11-29 AT AT01998363T patent/ATE465752T1/de active
- 2001-11-29 US US10/433,492 patent/US20040202676A1/en not_active Abandoned
- 2001-11-29 AU AU2002221518A patent/AU2002221518B2/en not_active Ceased
-
2003
- 2003-05-21 ZA ZA200303948A patent/ZA200303948B/en unknown
-
2007
- 2007-10-10 US US11/870,088 patent/US20090104223A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1346727B1 (en) | 2010-04-28 |
WO2002043756A2 (es) | 2002-06-06 |
AU2002221518B2 (en) | 2006-06-01 |
ZA200303948B (en) | 2004-03-30 |
BRPI0115859B8 (pt) | 2021-05-25 |
CN1477972A (zh) | 2004-02-25 |
WO2002043756A3 (es) | 2003-01-09 |
CA2429543C (en) | 2012-07-10 |
KR20030068161A (ko) | 2003-08-19 |
KR100873675B1 (ko) | 2008-12-11 |
ES2342150T3 (es) | 2010-07-02 |
AR031437A1 (es) | 2003-09-24 |
CN1253206C (zh) | 2006-04-26 |
BRPI0115859B1 (pt) | 2020-10-13 |
RU2266754C2 (ru) | 2005-12-27 |
US20090104223A1 (en) | 2009-04-23 |
CA2429543A1 (en) | 2003-05-20 |
US20040202676A1 (en) | 2004-10-14 |
JP2004529861A (ja) | 2004-09-30 |
AU2151802A (en) | 2002-06-11 |
PT1346727E (pt) | 2010-05-21 |
BR0115859A (pt) | 2003-12-30 |
ATE465752T1 (de) | 2010-05-15 |
DE60141978D1 (de) | 2010-06-10 |
JP4974441B2 (ja) | 2012-07-11 |
EP1346727A2 (en) | 2003-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60121136T2 (de) | Proteasom-influenzavirus-impfstoffzusammensetzung | |
RU2349342C2 (ru) | Менингококковые вакцины для введения через слизистую оболочку | |
Kang et al. | Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin | |
ES2924988T3 (es) | Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria | |
TW200722101A (en) | Novel composition | |
Azuar et al. | Cholic acid-based delivery system for vaccine candidates against group A streptococcus | |
JP2015038130A (ja) | 結核のワクチンおよびその使用方法 | |
CU23002A1 (es) | Método de obtención de agregados antigénicos y su uso en formulaciones | |
Jones et al. | Protollin™: a novel adjuvant for intranasal vaccines | |
JP2000512292A (ja) | 免疫刺激するリピド製剤 | |
JP2008528570A (ja) | ワクチンの有効性増強のためのアジュバント | |
Karimi et al. | Chitosan (CHT) and trimethylchitosan (TMC) nanoparticles as adjuvant/delivery system for parenteral and nasal immunization against Mycobacterium tuberculosis (MTb) ESAT-6 antigen | |
ES2645076T3 (es) | Adyuvante | |
CA2931139A1 (en) | Swine vaccine against prrs and lawsonia intracellularis | |
AU769390B2 (en) | Vaccine composition | |
AR031182A1 (es) | Metodo de obtencion de estructuras antigenicas que potencian la reactividad cruzada especifica y su uso en formulaciones | |
US10420836B2 (en) | Methods of immunizing a subject and compositions related thereto | |
Alshanqiti et al. | Adjuvants for Clostridium tetani and Clostridium diphtheriae vaccines updating | |
US20150086587A1 (en) | Vaccine adjuvant | |
KR101857839B1 (ko) | 개선된 백신 조성물들 | |
Alam et al. | Adjuvants in allergy: state of the art | |
AR038311A1 (es) | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes | |
Yang et al. | Immune response effects of diverse vaccine antigen attachment ways based on the self-made nanoemulsion adjuvant in systemic MRSA infection | |
WO2018030338A1 (ja) | アジュバント組成物 | |
TH55920B (th) | วิธีการสำหรับได้กลุ่มก้อนโมเลกุลแอนติเจนิก และการใช้ของมันในสูตรผสม |